4. Van den Hout HM, Hop W, Van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. *Pediatrics* 2003;112:332–340.
5. Bharati S, Serratto M, DuBrow I, et al. The conduction system in Pompe's disease. *Pediatr Cardiol* 1982;2:25–32.
6. Bulkley BH, Hutchins GM. Pompe's disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndrome. *Am Heart J* 1978;96:246–252.
7. Francesconi M, Auff E, Ursin C, Sluga E. [WPW syndrome combined with AV block 2 in an adult with glycogenosis (Type II)] *Wien Klin Wochenschr* 1982;94:401–404.
8. Tabarki B, Mahdhaoui A, Yacoub M, et al. [Familial hypertrophic cardiomyopathy associated with Wolff-Parkinson-White syndrome revealing type II glycogenosis]. *Arch Pediatr* 2002;9:697–700.
9. Ansong AK, Li JS, Nozik-Grayck E, et al. Electrocardiographic response to enzyme replacement therapy for Pompe disease. *Genet Med* 2006;8:297–301.
10. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease. *Neurology* 2007;68:99–109.
11. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. *Genet Med* 2001;3:132–138.
12. Van den Hout JM, Reuser AJ, de Klerk JB, et al. Enzyme therapy for Pompe disease with recombinant human alpha-glucosidase from rabbit milk. *J Inherit Metab Dis* 2001;24:266–274.
13. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. *Pediatrics* 2004;113:448–457.
14. Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. *Neuromuscul Disord* 2005;15:24–31.
15. Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. *J Pediatr* 2006;149:89–97.
16. FDA approves first treatment for Pompe's disease, 2006. Available at: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01365.html. Accessed February 12, 2008.
17. European Medicines Agency: Committee for Medicinal Products for Human use, 2006. Available at: http://www.emea.europa.eu/pdfs/human/press/pr/3279606en.pdf. Accessed February 12, 2008.
18. Cook AL, Kishnani PS, Carboni MP, et al. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease. *Genet Med* 2006;8:313–317.
19. Wang LY, Ross AK, Li JS, et al. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. *Paediatr Anaesth* 2007;17:738–748.
20. Ing RJ, Cook DR, Bengur RA, et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. *Paediatr Anaesth* 2004;14:514–519.
21. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. *Am J Cardiol* 1993;72:23B–25B.
22. Garson A Jr, Dick M II, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. *Circulation* 1993;87:1866–1872.
23. Vincent GM. Long QT syndrome. *Cardiol Clin* 2000;18:309–325.
24. Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. *Am J Cardiol* 1998;82:774–778.
25. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. *N Engl J Med* 2000;342:1778–1785.
26. Romeo F, Cianfrocca C, Pelliccia F, Colloridi V, Cristofani R, Reale R. Long-term prognosis in children with hypertrophic cardiomyopathy: an analysis of 37 patients aged less than or equal to 14 years at diagnosis. *Clin Cardiol* 1990;13:101–107.
27. Grimm W, Christ M, Bach J, Muller HH. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. *Circulation* 2003;108:2883–2891.
28. Azevedo VM, Santos MA, Albanesi Filho FM, Castier MB, Tura BR, Amino JG. Outcome factors of idiopathic dilated cardiomyopathy in children—a long-term follow-up review. *Cardiol Young* 2007;17:175–184.
29. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. *N Engl J Med* 2005;352:362–372.
30. Arad M, Moskowitz IP, Patel VV, et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. *Circulation* 2003;107:2850–2856.
31. Charron P, Villard E, Sebillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. *Heart* 2004;90:842–846.
32. Patel VV, Arad M, Moskowitz IP, et al. Electrophysiologic characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiac hypertrophy and Wolff-Parkinson-White syndrome. *J Am Coll Cardiol* 2003;42:942–951.
33. Sidhu JS, Rajawat YS, Rami TG, et al. Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. *Circulation* 2005;111:21–29.
34. Moon J, Sheppard M, Reed E, Lee P, Elliott PM, Pannell DJ. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. *J Cardiovasc Magn Reson* 2006;8:479–482.
35. Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. *Am J Cardiol* 2006;97:1515–1518.
36. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. *J Am Coll Cardiol* 2000;35:36–44.
37. Yi G, Elliott P, McKenna WJ, et al. QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. *Am J Cardiol* 1998;82:1514–1519.
38. Dritsas A, Sbarouni E, Gilligan D, Nihoyannopoulos P, Oakley CM. QT-interval abnormalities in hypertrophic cardiomyopathy. *Clin Cardiol* 1992;15:739–742.
39. Sun ZH, Happonen JM, Bennhagen R, et al. Increased QT dispersion and loss of sinus rhythm as risk factors for late sudden death after Mustard or Senning procedures for transposition of the great arteries. *Am J Cardiol* 2004;94:138–141.
40. Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. *Br Heart J* 1990;63:342–344.
41. Bonaduce D, Petretta M, Marciano F, et al. Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. *Am Heart J* 1999;138:273–284.
42. Brouwer J, van Veldhuisen DJ, Man in 't Veld AJ, et al. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. *J Am Coll Cardiol* 1996;28:1183–1189.

Erratum

In the article "Influence of Genetic Discrimination Perceptions and Knowledge on Cancer Genetics Referral Practice Among Clinicians" in the September issue of *Genetics in Medicine*, an asterisk was missing in the legend for Figure 1. The legend should have stated: $*P < 0.001$.

Lowstuter KJ, Sand S, Blazer KR, et al. Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. *Genet Med* 10:691–698.